“Supercharged Cells” for Delivery of Recombinant Human Iduronate-2-Sulfatase

This publication has 23 references indexed in Scilit:

• Retroviral-Mediated Transfer of the Iduronate-2-Sulfatase Gene into Lymphocytes for Treatment of Mild Hunter Syndrome (Mucopolysaccharidosis Type II). University of Minnesota Medical School, Minneapolis, Minnesota
  Human Gene Therapy, 1996
• Preclinical Studies of Lymphocyte Gene Therapy for Mild Hunter Syndrome (Mucopolysaccharidosis Type II)
  Human Gene Therapy, 1996
• Saturation mutagenesis at dihydrofolate reductase codons 22 and 31 A variety of amino acid substitutions conferring methotrexate resistance
  Biochemical Pharmacology, 1994
• Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.
  Proceedings of the National Academy of Sciences, 1993
• Comparison of the Expression of a Mutant Dihydrofolate Reductase under Control of Different Internal Promoters in Retroviral Vectors
  Human Gene Therapy, 1992
• LYSOSOMAL STORAGE DISEASES
  Annual Review of Biochemistry, 1991
• Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA.
  Proceedings of the National Academy of Sciences, 1990
• Multiple transfer of lysosomal enzymes from normal lymphocytes to I-Cell disease fibroblasts
  Cell Biology International Reports, 1987
• A clinical and genetic study of Hunter's syndrome. 2 Differences between the mild and severe forms
  Journal of Medical Genetics, 1982
• REVERSAL OF CLINICAL FEATURES OF HURLER'S DISEASE AND BIOCHEMICAL IMPROVEMENT AFTER TREATMENT BY BONE-MARROW TRANSPLANTATION
  The Lancet, 1981